ArticleExperimental and therapeutic medicine2022
Micropulse vs. continuous wave transscleral cyclophotocoagulation in neovascular glaucoma.
Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- The efficacy and safety of anti-vascular endothelial growth factor combined with Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- The efficacy and safety of micropulse transscleral laser treatment in glaucoma: a systematic review and meta-analysis.BMC ophthalmology · 2023Pooled it
- Comparative Efficacy and Safety of Micropulse Versus Continuous-Wave Transscleral Cyclophotocoagulation in the Management of Refractory Glaucoma: A Prospective Cohort Study.Journal of glaucoma · 2026Trial
- The efficacy of MicroPulse Transscleral Laser Therapy as primary surgical treatment in various types of glaucoma resistant to medical treatment: a retrospective analysis.BMC ophthalmology · 2026Article
- Analysis of Pediatric Secondary Glaucoma Patients Treated with Micropulse Transscleral Cyclophotocoagulation (MP-TSCPC).Life (Basel, Switzerland) · 2026Article
- Comparison of outcomes of continuous-wave and micropulse trans-scleral cyclophotocoagulation: A retrospective cohort study.European journal of ophthalmology · 2025Article
- Comparison of treatment outcomes between slow coagulation transscleral cyclophotocoagulation and micropulse transscleral laser treatment.Scientific reports · 2024Article
- Comparison of Efficacy of Micropulse Laser Settings for Glaucoma Management.Journal of clinical medicine · 2024Article
- Initial Clinical Experience with Ahmed Valve in Romania: Five-Year Patient Follow-Up and Outcomes.Bioengineering (Basel, Switzerland) · 2024Article
- Surgical Treatment of Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy in Japanese Patients without the Use of Glaucoma Drainage Devices.Journal of clinical medicine · 2024Article
- Uveoscleral Outflow Routes after MicroPulse Laser Therapy for Refractory Glaucoma: An Optical Coherence Tomography Study of the Sclera.International journal of molecular sciences · 2024Article
- A Systematic Review of Cyclophotocoagulation Techniques: Continuous Wave Versus Micropulse for Glaucoma Treatment.Beyoglu eye journal · 2024Review
- Malignant glaucoma treated by low-dose laser cycloplasty: a 1-year multicenter prospective non-comparative study.International journal of ophthalmology · 2024Article
- Efficacy and Safety of Diode Laser Transscleral Cyclophotocoagulation in Patients with Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy.Frontiers in endocrinology · 2023Review
- Surgical Treatment in Silicone Oil-Associated Glaucoma.Diagnostics (Basel, Switzerland) · 2022Review
- Early Postoperative Intraocular Pressure Profile Following Micropulse vs Continuous Wave Transscleral Cyclophotocoagulation: Cohort Study.Journal of current glaucoma practiceArticle
- Clinical Outcomes of MicroPulse Transscleral Laser Therapy with the Revised P3 Delivery Device.Journal of current glaucoma practiceArticle
- Neural Network - Supported Prognostic Assessment of Apoptotic and Inflammatory Markers in Neovascular Glaucoma.Romanian journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neovascular glaucoma (NVG) is a refractory form of glaucoma, associated with important morbidity, for which no consensus exists regarding the optimal choice of therapy. The primary aim of our study was to compare the performances of micropulse transscleral cyclophotocoagulation (MP-TSCPC) and continuous wave transscleral cyclophotocoagulation (CW-TSCPC) in the treatment of neovascular glaucoma (NVG). A total of 24 eyes for MP-TSCPC and 22 eyes for CW-TSCPC, all with NVG were included. The procedures were performed using either the Iridex Cyclo G6 (IRIDEX Laser System), the MP3, or the G-Probe devices. Intraocular pressure (IOP), visual acuity (VA), the mean number of antiglaucoma medications, and postoperative complications were monitored. The minimum follow-up was 12 months. The success rate at 12 months was 54.5% in the CW-TSCPC group and 33.3% in the MP-TSCPC group. The mean IOP at baseline was 35.82 mm Hg for CW-TSCPC and 34.71 mm Hg for MP-TSCPC. The change from baseline in IOP at 12 months was 11.95 mm Hg in the CW-TSCPC group and -8.04 mm Hg in the MP-TSCPC group. There was a significant difference in the occurrence of serious complications (worsening of VA, hypotony, and phthisis bulbi) between the two methods, with CW-TSCPC associated with more important adverse effects (P=0.045). There was a decrease in the number of topical antiglaucoma medications in both groups: in the MP-TSCPC group from a mean number of 2.6 at baseline, to 1.7 at 3 months, followed by a slight increase to 2.1 at 12 months and in the CW-TSCPC group from 2.8 at baseline, to 1.4 at 3 months and 1.9 at 12 months. Our study concluded that both MP-TSCPC and CW-TSCPC could manage NVG, but, while CW-TSCPC revealed higher IOP control in the long term (which did not reach statistical significance), it also had a significantly lower safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.